26-Apr-2024 15:49 |
3.73p |
4,800 |
£179 |
Sell |
O |
26-Apr-2024 15:37 |
3.73p |
2,237 |
£84 |
Sell |
O |
26-Apr-2024 15:30 |
3.78p |
100,000 |
£3,775 |
Buy |
O |
26-Apr-2024 15:20 |
3.74p |
300,000 |
£11,212 |
Sell |
O |
26-Apr-2024 15:18 |
3.75p |
13,342 |
£500 |
Sell |
O |
26-Apr-2024 15:05 |
3.73p |
9,005 |
£336 |
Sell |
O |
26-Apr-2024 14:27 |
3.73p |
7,101 |
£265 |
Sell |
O |
26-Apr-2024 13:15 |
3.73p |
42,169 |
£1,574 |
Sell |
O |
26-Apr-2024 11:14 |
3.78p |
10,000 |
£378 |
Sell |
O |
26-Apr-2024 10:52 |
3.73p |
18,960 |
£707 |
Sell |
O |
26-Apr-2024 10:09 |
3.82p |
5,192 |
£198 |
Buy |
O |
26-Apr-2024 08:21 |
3.70p |
40 |
£2 |
Sell |
O |
26-Apr-2024 08:03 |
3.82p |
2,044 |
£78 |
Buy |
O |
15:49 |
4,800 @ 3.73p |
15:37 |
2,237 @ 3.73p |
15:30 |
100,000 @ 3.78p |
15:20 |
300,000 @ 3.74p |
15:18 |
13,342 @ 3.75p |
CFO |
Charles Osborne |
CEO |
Christopher von Jako |
Top of Page
You are here:
research